Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 29
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Cabaletta Bio Inc
CABA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.52
0.065
4.47%
Ult. Agg.: Oct 28, 7:20 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Cabaletta Bio Financials
Cabaletta Bio (CABA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from
Benzinga Newsdesk
PRO
Cabaletta Bio Q1 EPS $(0.39), Inline
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.
Benzinga Newsdesk
PRO
Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the
Benzinga Newsdesk
PRO
Cabaletta Bio Q3 EPS $(0.44) Beats $(0.45) Estimate; Cash, Cash Equivalents And Short-Term Investments Of $159.9M Provides Cash Runway Into 2H 2026
Benzinga Newsdesk
PRO
Cabaletta Bio Q2 EPS $(0.73) Misses $(0.61) Estimate
Benzinga Newsdesk
PRO
Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the
Benzinga Newsdesk
